Valeant's SILIQ Will Be Priced At $3,500 A Month
What Is SILIQ?
The U.S. Food and Drug Administration approved the Biologics License Application for SILIQ, which is a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis for the treatment of moderate to severe plaque psoriasis in adult patients.
Valeant's Patient Access and Pricing Committee will list the SILIQ injection at $3,500 per month, which the company noted is the lowest injectable treatment currently on the market.
The company will also include SILIQ in its patient access program, which offers financial support and access to patients. Sales and marketing of the therapy are expected to begin in the United States in the bottom half of 2017.
SILIQ does have a Black Box Warning for risk in patients with a history of suicidal thoughts or behavior.
"The Patient Access and Pricing Committee was constructed to help our company ensure patients have the best possible access to our products. Our goal with SILIQ is to provide outstanding efficacy while being the most affordable injectable biologic for patients with moderate-to-severe plaque psoriasis," said Joseph Papa, chairman and CEO of Valeant.
In Friday's pre-market session, shares of Valeant were up 1.24 percent at $8.99.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.